Malignant brain and spinal cord tumors are projected to cause approximately 24,740 new diagnoses and 18,350 deaths in the United States in 2026, with an overall 5-year relative survival rate near 32.9%. Age drives outcomes sharply: among more than 40,000 glioblastoma patients in a SEER analysis, median survival was 4 months for patients older than 65 versus 19 months for younger patients, and nearly one-third of all glioblastoma diagnoses occur in adults 65 and older. Because this population skews toward Medicare-age adults, precise documentation of primary versus metastatic disease and active treatment or surveillance status is among the highest-value actions a primary care team can take.
AAVBC's Brain Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity, HCC/RAF V28 mapping, atypical presentation and geriatric risk factors, Comprehensive Geriatric Assessment and comorbidity screening, MEAT documentation standards, NCCN-aligned treatment by molecular subtype, and coding reminders with case examples. Grounded in NCCN v1.2026 guidance and current CMS-HCC V28 methodology, this guide supports consistent, individualized clinical decision-making, helping care teams recognize atypical presentations early and document clinical complexity with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of brain cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Malignant brain and spinal cord tumors are projected to cause approximately 24,740 new diagnoses and 18,350 deaths in the United States in 2026, with an overall 5-year relative survival rate near 32.9%. Age drives outcomes sharply: among more than 40,000 glioblastoma patients in a SEER analysis, median survival was 4 months for patients older than 65 versus 19 months for younger patients, and nearly one-third of all glioblastoma diagnoses occur in adults 65 and older. Because this population skews toward Medicare-age adults, precise documentation of primary versus metastatic disease and active treatment or surveillance status is among the highest-value actions a primary care team can take.
AAVBC's Brain Cancer Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity, HCC/RAF V28 mapping, atypical presentation and geriatric risk factors, Comprehensive Geriatric Assessment and comorbidity screening, MEAT documentation standards, NCCN-aligned treatment by molecular subtype, and coding reminders with case examples. Grounded in NCCN v1.2026 guidance and current CMS-HCC V28 methodology, this guide supports consistent, individualized clinical decision-making, helping care teams recognize atypical presentations early and document clinical complexity with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of brain cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
